丙戊酸镁缓释剂对躁狂发作预防效果的评价  

Prophylactic Effects of Magnesium Valproa Tesustained Release Agent in Manic Episode

作　　者：王新法[1] 王领军[1] 吴焕[2] 

机构地区：[1]河南省精神病医院精神科,河南新乡453002 [2]新乡医学院管理学院

出　　处：《中国误诊学杂志》2010年第18期4293-4294,共2页Chinese Journal of Misdiagnostics

摘　　要：目的评价丙戊酸镁缓释剂预防躁狂发作的疗效和安全性。方法 110例躁狂发作患者出院时分别应用丙戊酸镁缓释剂和碳酸锂进行预防性治疗,观察12个月,使用Bech-Refaelse躁狂量表(BRMS)、不良反应量表(TESS)评定疗效和安全性。结果两组间BRMS评分在出院6个月和12个月时差异有统计学意义;研究组有效率83%,对照组有效率64%,不良反应发生率研究组20%,对照组44%,差异有统计学意义。结论丙戊酸镁缓释剂预防躁狂发作的疗效优于碳酸锂且安全性高。Objective To evaluate the efficacy and safety of magnesium valproa tesustained release agent in treatment of manic episode.Methods 110 patients with manic episodeat discharge were assigned to research group（n=60） received magnesium valproa tesustained release agent and control group（n=50） received lithium carbonate for 12 months to proceedprophylactic treatment according to original drugs.Efficacies were assessed with the BRMS and adverse reactions with the TESS.Results There were significant differences in the BRMS scores between the two groups in the 6th and 12th month after discharge;the total effective rates were respectively 83% in the research and 64% in the control,the difference was significant;the incidences of adverse reactions were respectively 20% in the research and 44% in the control group,the difference was very significant.Conclusions Magnesium valproa tesustained release agent has an advantage over lithium carbonate and higher safety in preventing manic episode.

关 键 词：双相情感障碍/预防和控制 丙戊酸/治疗应用 抗躁狂药/治疗应用 人类 

分 类 号：R749.41[医药卫生—神经病学与精神病学]